These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38514083)

  • 21. A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology.
    Askoxylakis V; Garcia-Boy R; Rana S; Krämer S; Hebling U; Mier W; Altmann A; Markert A; Debus J; Haberkorn U
    PLoS One; 2010 Dec; 5(12):e15962. PubMed ID: 21209841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with (68)Ga-Labeled Benzenesulfonamides.
    Lau J; Zhang Z; Jenni S; Kuo HT; Liu Z; Vullo D; Supuran CT; Lin KS; Bénard F
    Mol Pharm; 2016 Mar; 13(3):1137-46. PubMed ID: 26866675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
    Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
    Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical Evaluation of
    Ganguly T; Bauer N; Davis RA; Foster CC; Harris RE; Hausner SH; Roncali E; Tang SY; Sutcliffe JL
    J Nucl Med; 2023 Apr; 64(4):639-644. PubMed ID: 36207137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
    Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
    Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells.
    van Lith SAM; Huizing FJ; Franssen GM; Hoeben BAW; Lok J; Doulkeridou S; Boerman OC; Gotthardt M; van Bergen En Henegouwen PMP; Bussink J; Heskamp S
    Mol Pharm; 2022 Oct; 19(10):3511-3520. PubMed ID: 35044182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PET imaging and pharmacological therapy targeting carbonic anhydrase-IX high-expressing tumors using US2 platform based on bivalent ureidosulfonamide.
    Iikuni S; Watanabe H; Shimizu Y; Nakamoto Y; Ono M
    PLoS One; 2020; 15(12):e0243327. PubMed ID: 33296398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
    Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
    J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer.
    Lee BS; Kim MH; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim HS; Kim MH; Kil HS; Han SJ; Lee YJ; Lee KC; Lim SM; Chi DY
    Mol Cancer Ther; 2021 Dec; 20(12):2410-2419. PubMed ID: 34725194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
    Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
    Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
    Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
    Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide.
    El Fakiri M; Regupathy AR; Uhlmann L; Ayada N; Geis NM; Domogalla LC; Lahdenranta J; Blakeman B; Wood F; Meyer PT; Huxley P; Eder M; Mudd GE; Eder AC
    Theranostics; 2024; 14(12):4701-4712. PubMed ID: 39239524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors].
    Zhang W; Yu WJ; Xia Y; Liu Y; Liu XL; Zhuang J; Li YJ
    Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):442-5. PubMed ID: 24246861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
    Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
    Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9.
    Petrul HM; Schatz CA; Kopitz CC; Adnane L; McCabe TJ; Trail P; Ha S; Chang YS; Voznesensky A; Ranges G; Tamburini PP
    Mol Cancer Ther; 2012 Feb; 11(2):340-9. PubMed ID: 22147747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.
    Minn I; Koo SM; Lee HS; Brummet M; Rowe SP; Gorin MA; Sysa-Shah P; Lewis WD; Ahn HH; Wang Y; Banerjee SR; Mease RC; Nimmagadda S; Allaf ME; Pomper MG; Yang X
    Oncotarget; 2016 Aug; 7(35):56471-56479. PubMed ID: 27437764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative Imaging of Hypoxic CAIX-Positive Tumor Areas with Low Immune Cell Infiltration in Syngeneic Mouse Tumor Models.
    Boreel DF; Span PN; Kip A; Boswinkel M; Peters JPW; Adema GJ; Bussink J; Heskamp S
    Mol Pharm; 2023 Apr; 20(4):2245-2255. PubMed ID: 36882391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.
    Garousi J; Huizing FJ; Vorobyeva A; Mitran B; Andersson KG; Leitao CD; Frejd FY; Löfblom J; Bussink J; Orlova A; Heskamp S; Tolmachev V
    Sci Rep; 2019 Oct; 9(1):14907. PubMed ID: 31624303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding of the phage display derived peptide CaIX-P1 on human colorectal carcinoma cells correlates with the expression of carbonic anhydrase IX.
    Askoxylakis V; Ehemann V; Rana S; Krämer S; Rahbari NN; Debus J; Haberkorn U
    Int J Mol Sci; 2012 Oct; 13(10):13030-48. PubMed ID: 23202936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.